Adalimumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), NICE (England) and SMC (Scotland), among others, recommended or restricted adalimumab, while NYE METODER (Norway) did not recommend it.
AWMSG (Wales) has been easier on adalimumab than on its own caseload: it refused 1 of 5 decisive submissions here (20%), against a base rate of 49% across everything it has assessed.
The file has been open for more than a decade: 22.8 years separate the first record, 22 Sep 2003 at TLV (Sweden), from the most recent, 21 Jul 2026 at CONITEC (Brazil).
AWMSG (Wales) changed its position: not recommended on 16 Jan 2013, recommended by 16 Mar 2022, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for adalimumab, 6 submissions were never made and 3 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 18 of 133 records date from 2023 or later.
The programme is broad: 58 distinct indication wordings are recorded for adalimumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
40 of these 133 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess adalimumab, on 22 Sep 2003; NYE METODER (Norway) did not open a file until 16 Dec 2018 — an unusually long tail of 15.2 years between the earliest and latest system to look at it.
The record arrives in waves: 18 separate years each carry two or more decisions, spread across 22 years in total.
10 of the 11 agencies here assessed adalimumab more than once, PBAC (Australia) most often at 40 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for adalimumab.
The full ledger for adalimumab reads 75 recommended, 15 not recommended, 15 restricted and 7 superseded, with 21 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Crohn diseaseUlcerative colitisActive juvenile idiopathic arthritisComplex refractory fistulising Crohn diseaseActive rheumatoid arthritis Psoriatic arthritisAnkylosing s… | Recommended | source |
| TLV (Sweden) | 28 Oct 2025 | Yuflyma ingår i högkostnadsskyddet | general subsidy | source |
| PHARMAC (New Zealand) | 1 Jul 2023 | Citrate free formulation | funding application decided · decision reached | source |
| HAS (France) | 13 Jun 2018 | Indication extension | SMR insufficient · ASMR IV | source |
| AWMSG (Wales) | 22 Jul 2016 | Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response… | excluded, NICE appraised | source |
128 further decisions for adalimumab, across 11 agencies, are not shown here. They include the most recent record on file, 21 Jul 2026 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 73 further source documents.
Related molecules
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
- lenalidomide — same ATC class L04A — Immunosuppressants
Coverage: 133 decisions for adalimumab from 11 agencies, 2003 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.